Recombinant adenoviruses and use thereof
AssigneesBeth Israel Deaconess Medical Center, Inc., Washington University
InventorsDan H. Barouch, Herbert Virgin, IV, Peter Abbink
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
Claims29
A recombinant adenovirus comprising a nucleotide sequence having at least 90% sequence identity over the entire sequence of any one of SEQ ID NOs:
- 10 and 12, or a complementary sequence to a nucleotide sequence having at least 90% sequence identity over the entire sequence of any one of SEQ ID NOs:
- 10 and 12;
- wherein said recombinant adenovirus comprises a deletion in or of an E1 region, an E3 region, and/or an E4 region, said deletion rendering said recombinant adenovirus a replication-defective virus.
A method of producing a recombinant adenovirus comprising transfecting a cell with:
- (a) an isolated polynucleotide comprising a nucleotide sequence having at least 90% sequence identity over the entire sequence of any one of SEQ ID NOs:
- 10 and 12, or a complementary sequence to a nucleotide sequence having at least 90% sequence identity over the entire sequence of any one of SEQ ID NOs:
- 10 and 12 or (b) a recombinant vector comprising said polynucleotide;
- culturing said cell in a suitable medium to allow replication of said polynucleotide or vector in said cell;
- and harvesting produced recombinant adenovirus from said medium and/or said cell.
Dependencies are inferred from the claim text.